Last reviewed · How we verify

Gan and Lee Pharmaceuticals, USA — Portfolio Competitive Intelligence Brief

Gan and Lee Pharmaceuticals, USA pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 6 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
GZR4 Injection GZR4 Injection phase 3 Glucagon receptor antagonist Glucagon receptor Diabetes
Gan & Lee Insulin Glargine Injection Gan & Lee Insulin Glargine Injection phase 3 Long-acting basal insulin Insulin receptor Diabetes

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Merck Sharp & Dohme LLC · 2 shared drug classes
  2. Novo Nordisk A/S · 2 shared drug classes
  3. Allergan · 1 shared drug class
  4. Claes-Göran Östenson · 1 shared drug class
  5. Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · 1 shared drug class
  6. GlaxoSmithKline · 1 shared drug class
  7. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 1 shared drug class
  8. Life for a Child Program, Diabetes Australia · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Gan and Lee Pharmaceuticals, USA:

Cite this brief

Drug Landscape (2026). Gan and Lee Pharmaceuticals, USA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/gan-and-lee-pharmaceuticals-usa. Accessed 2026-05-17.

Related